BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Purpose
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.
Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Head and Neck Squamous Cell Carcinoma
- Hypopharyngeal Squamous Cell Carcinoma
- Laryngeal Squamous Cell Carcinoma
- Lip and Oral Cavity Squamous Cell Carcinoma
- Melanoma
- Oropharyngeal Squamous Cell Carcinoma
- Stage III Hypopharyngeal Carcinoma AJCC v8
- Stage III Laryngeal Cancer AJCC v8
- Stage III Lip and Oral Cavity Cancer AJCC v8
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IV Hypopharyngeal Carcinoma AJCC v8
- Stage IV Laryngeal Cancer AJCC v8
- Stage IV Lip and Oral Cavity Cancer AJCC v8
- Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- STEP 1 - SPECIMEN SUBMISSION
- Participants must have histologically confirmed melanoma that is stage III or IV,
unresectable, recurrent, or metastatic non-uveal melanoma OR Participants must have
histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) that is
either locally recurrent and non-amendable to curative therapy (e.g., radiation,
surgery) or metastatic. The primary tumor location must be the oropharynx, oral
cavity, hypopharynx, or larynx. Primary tumor site of nasopharynx (any histology) or
unknown primary tumor are not eligible
- Note: For participants with primary oropharyngeal cancer, human papillomavirus
(HPV) or p16 status must be known prior to step 1 registration
- Participants must have disease presentation consistent with measurable disease. Note:
Current disease measurements will not be required until step 2 registration
- Participants must have had documented progression within 12 weeks after the last dose
of PD-1 checkpoint inhibition-based therapy. Participants must have been receiving
checkpoint inhibition for a minimum of 6 weeks. Participants who recur during adjuvant
anti-PD1 treatment or within 12 weeks of completion of adjuvant anti-PD1 treatment are
eligible if they have measurable disease and are considered unresectable
- Participants with known human immunodeficiency virus (HIV)-infection must be receiving
anti-retroviral therapy and have an undetectable viral load test within 6 months prior
to step 1 registration
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have
undetectable HBV viral load within 28 days prior to step 1 registration
- Participants with a history of hepatitis C virus (HCV) infection must have no
detectable viral load within 28 days prior to step 1 registration
- Participants must not have an active infection requiring systemic therapy (except HBV,
HCV or HIV as mentioned above)
- Participants must not have known history of congenital long QT syndrome and must not
have experienced unstable angina pectoris, clinically significant cardiac arrhythmias,
or stroke (transient ischemic attack [TIA] or other ischemic event) within 90 days
prior to Step 1 registration
- Participants must not have experienced myocardial infarction or thromboembolic event
requiring anticoagulation within 90 days prior to step 1 registration, unless
clinically stable with ongoing medical management
- Participants must have recovered to baseline or =< grade 1 Common Terminology Criteria
for Adverse Events (CTCAE) version (v) 5 toxicities related to any prior treatments,
unless adverse events are deemed clinically nonsignificant by the treating
investigator or stable on supportive therapy
- Participants must not have received more than one prior primary radiotherapy regimen,
curative or adjuvant, to the mucosal surfaces of the head and neck, with the
additional following criteria:
- If the primary radiation is combined with chemotherapy, a minimum of 16 weeks
will be required to have elapsed between the end of radiotherapy and step 1
registration. If the radiation is given alone, a minimum of 8 weeks will be
required to have elapsed between the end of radiotherapy and step 1 registration
- Additional palliative radiotherapy regimens are permitted but cannot have been
administered to previously treated tissue (i.e., overlapping fields are excluded)
with the exception of central nervous system (CNS) radiation and must be
completed at least 4 weeks prior to step 1 registration
- Treatment areas should be healed with no sequelae from radiation therapy (RT)
that would predispose to fistula formation
- Participants must not have received prior treatment with anti-VEGF therapies for any
reason
- Participants must be >= 18 years of age
- Participants must have a Zubrod Performance Status 0 or 1
- Participants must have adequate cardiac function. Participants with known history or
current symptoms of cardiac disease, or history of treatment with cardiotoxic agents,
must have a clinical risk assessment of cardiac function using the New York Heart
Association Functional Classification and must be class 2B or better to be eligible
for this trial
- Participants must not have any known significant organ disfunction that, in the
opinion of the treating investigator, may impact suitability for receiving combination
nivolumab/cabozantinib treatment
- Participants must be able to take oral medication without breaking, opening, crushing,
dissolving or chewing capsules
- Participants must not have malabsorption syndrome
- Participants must not have active autoimmune disease requiring systemic steroids
(equivalent of > 10mg of prednisone) or other immune suppression. Exceptions:
- Type 1 diabetes mellitus
- Endocrinopathy only requiring hormone replacement
- Skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic
treatment
- Conditions not expected to recur in the absence of an external trigger
- Participants must not have received an organ allograft
- Participants must not have a history of hemoptysis (defined as >= 1/2 tsp of bright
red blood per day) or tumor bleeding within 90 days prior to step 1 registration
- Participants must not have any of the following criteria due to the possibility of
increased risk for tumor bleeding with cabozantinib therapy:
- Prior carotid bleeding
- Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by
imaging studies
- Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as
shown unequivocally by imaging studies
- Any prior history of bleeding related to the current head and neck cancer
- History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode
of coughing) within 3 months
- Participants must not require concomitant anticoagulation with coumarin agents (e.g.,
warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor
betrixaban, or platelet inhibitors (e.g., clopidogrel)
- Participants must not require anticoagulants except for the following:
- Prophylactic use of low-dose aspirin for cardio-protection (per local
applicable guidelines) and low-dose low molecular weight heparins (LMWH).
- Therapeutic doses of LMWH or anticoagulation with direct factor Xa
inhibitors, rivaroxaban, edoxaban, or apixaban in participants without known
brain metastases who are on a stable dose of the anticoagulant for at least
1 week prior to step 1 registration without clinically significant
hemorrhagic complications from the anticoagulation regimen or the tumor
- Participants must not have evidence of preexisting uncontrolled hypertension 28 days
prior to step 1 registration as documented by baseline blood pressure reading with
systolic blood pressure >= 150 mmHg and/or diastolic blood pressure >= 90 mmHg.
Participants on antihypertensive therapies with controlled blood pressure are eligible
- Participants must not have a prior or concurrent malignancy whose natural history or
treatment (in the opinion of the treating physician) has the potential to interfere
with the safety or efficacy assessment of the investigational regimen
- Participants must not be pregnant or nursing due to the known safety profiles of the
drugs in this study. Individuals who are of reproductive potential must have agreed to
use an effective contraceptive method with details provided as a part of the consent
process. A person who has had menses at any time in the preceding 12 consecutive
months or who has semen likely to contain sperm is considered to be of "reproductive
potential. In addition to routine contraceptive methods, "effective contraception"
also includes refraining from sexual activity that might result in pregnancy and
surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention)
including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion and
vasectomy with testing showing no sperm in the semen
- Have an adequate archival tissue specimen verified by the local pathologist and
documented on the Pathology Review Form from a procedure obtained after the
development of resistance to anti-PD-1/L1 therapy. Archival tissue must consist of
tumor block or at least 1 H&E-stained 4-5 micron slide and 20 freshly cut serially
sectioned and numbered 4-5 micron unstained, uncharged slides OR
Be willing to undergo research biopsy AND have tumor accessible for biopsy based on the
following criteria:
- Mediastinal, laparoscopic, gastrointestinal, or bronchial endoscopic biopsies can be
obtained incidentally to a clinically necessary procedure and NOT for the sole purpose
of the clinical trial
- Acceptable biopsy procedures are:
- Percutaneous biopsy with local anesthetic and/or sedation with an expected risk
of severe complications < 2%
- Direct transoral biopsy (with or without local anesthetic and/or sedation) with
an expected risk of severe complications < 2%
- Excisional cutaneous biopsy with local anesthetic and/or sedation with an
expected risk of severe complications < 2%
- Biopsy with removal of additional tumor tissue during a medically necessary
mediastinoscopy, laparoscopy, gastrointestinal endoscopy, bronchoscopy or
craniotomy. No open surgical, laparoscopic or endoscopic procedure should be
performed solely to obtain a biopsy for this protocol
- Removal of additional tumor tissue during a medically necessary surgical
procedure
- Participants must submit whole blood for germline genomic analysis
- Participants must have been offered the opportunity to participate in
specimen banking
- Note: As a part of the Oncology Patient Enrollment Network (OPEN)
registration process the treating institution's identity is provided in
order to ensure that the current (within 365 days) date of institutional
review board approval for this study has been entered in the system
- Participants must be informed of the investigational nature of this study and must
sign and give informed consent in accordance with institutional and federal guidelines
- Participants with impaired decision-making capacity are eligible as long as their
neurological or psychological condition does not preclude their safe participation in
the study (e.g., tracking pill consumption and reporting adverse events to the
investigator)
- STEP 2 TREATMENT REGISTRATION
- Note: No tests or exams are required to be repeated for Step 2 registration
(Treatment). However, participants who are known to have a change in eligibility
status after Step 1 registration are not eligible for Step 2 registration
- Participants must have been eligible for step 1 registration continue to meet
eligibility for step 1 registration prior to step 2 registration.
- Participants must have had their tumor tissue submitted via the Southwest
Oncology Group (SWOG) Specimen Tracking System prior to step 2 registration
- Participants registered during stage II of the protocol must have received
assignment to an open cohort from the SWOG Statistics and Data Management Center
based on their biomarker screening profile (not applicable for patients
registered during stage I of the protocol)
- Participants must have measurable disease. All measurable disease must be
assessed within 28 days prior to step 2 registration. All non-measurable disease
must be assessed within 42 days prior to step 2 registration. Note: All disease
must be assessed and documented on the Baseline Tumor Assessment Form (Response
Evaluation Criteria in Solid Tumors [RECIST] 1.1)
- For melanoma participants, CT chest, abdomen and pelvis must be obtained. For
HNSCC participants, CT neck and chest must be obtained. Further imaging (i.e., MR
brain, CT abdomen/pelvis or extremities, bone scan) will be performed as deemed
appropriate by the treating physician
- Participants with treated brain metastases must have no evidence of progression
on the follow-up brain imaging after central nervous system (CNS)-directed
therapy
- Participants must not have experienced any significant health changes that, in
the opinion of the treating investigator, may impact continued suitability for
receiving combination nivolumab/cabozantinib treatment
- Participants with treated brain metastases must have discontinued steroid
treatment at least 14 days prior to step 2 registration
- Participants must not have received investigational agents or monoclonal
antibodies (except Food and Drug Administration [FDA] approved supportive care
antibodies, such as denosumab) within 28 days prior to step 2 registration
- Participants must not have received surgery, chemotherapy, radiation therapy,
biologic agents, or steroids within 14 days prior to step 2 registration.
- Participants must not have received administration of a live, attenuated vaccine
within 30 days prior to step 2 registration. Note: Participants may have received
a messenger ribonucleic acid (mRNA) or viral vector-based coronavirus disease
2019 (COVID-19) vaccine within 30 days prior to step 2 registration
- Participants must not have received administration of any strong CYP3A4 inducers,
such as but not limited to rifampin, carbamazepine, enzalutamide, mitotane,
phenytoin and St. John's wort, within 14 days prior to step 2 registration
- Participants must not have received administration of any strong CYP3A4
inhibitors, such as but not limited to clarithromycin, itraconazole,
ketoconazole, grapefruit juice, indinavir, nelfinavir, ritonavir, nefazodone,
saquinavir, and telithromycin, within 5 times the half-life of the CYP3A
inhibitor prior to step 2 registration
- Participants must have a history and physical examination performed within 28
days prior to step 2 registration
- Leukocytes >= 3,000/uL (within 28 days prior to step 2 registration)
- Absolute neutrophil count >= 1,500/uL (within 28 days prior to step 2
registration)
- Platelets >= 100,000/uL (within 28 days prior to step 2 registration)
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) or =< 3 x ULN
for participants with Gilbert's disease (within 28 days prior to step 2
registration)
- Aspartate aminotransferase (AST) =< 3 x institutional ULN (within 28 days prior
to step 2 registration)
- Alanine aminotransferase (ALT) =< 3 x institutional ULN (within 28 days prior to
step 2 registration)
- Urinalysis: For baseline value (no required value for eligibility)
- Measured (OR calculated) creatinine clearance >= 30 mL/min using the following
Cockcroft-Gault Formula. This specimen must have been drawn and processed within
28 days prior to step 2 registration
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Treatment (nivolumab and cabozantinib) |
Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cabozantinib PO daily. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans and collection of blood samples throughout the trial. Patients undergo a tumor biopsy during screening and optionally during follow-up. |
|
Recruiting Locations
Phoenix, Arizona 85054
Site Public Contact
855-776-0015
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Aurora, Colorado 80045
Site Public Contact
888-336-8262
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Fort Collins, Colorado 80528
Loveland, Colorado 80538
Site Public Contact
970-203-7083
Newark, Delaware 19713
Newark, Delaware 19713
Jacksonville, Florida 32224-9980
Site Public Contact
855-776-0015
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83686
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Twin Falls, Idaho 83301
Aurora, Illinois 60504
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
DeKalb, Illinois 60115
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Geneva, Illinois 60134
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Macomb, Illinois 61455
Mattoon, Illinois 61938
O'Fallon, Illinois 62269
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Warrenville, Illinois 60555
Washington, Illinois 61571
Yorkville, Illinois 60560
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Ankeny, Iowa 50023
Site Public Contact
515-282-2921
Boone, Iowa 50036
Site Public Contact
515-956-4132
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Clive, Iowa 50325
Site Public Contact
515-241-3305
Clive, Iowa 50325
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Boston, Massachusetts 02111
Springfield, Massachusetts 01199
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Detroit, Michigan 48201
Farmington Hills, Michigan 48334
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49009
Lansing, Michigan 48912
Livonia, Michigan 48154
Muskegon, Michigan 49444
Norton Shores, Michigan 49444
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Detroit Lakes, Minnesota 56501
Duluth, Minnesota 55805
Edina, Minnesota 55435
Fosston, Minnesota 56542
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Minneapolis, Minnesota 55407
Park Rapids, Minnesota 56470
Rochester, Minnesota 55905
Site Public Contact
855-776-0015
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Virginia, Minnesota 55792
Woodbury, Minnesota 55125
Cape Girardeau, Missouri 63703
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Bellevue, Nebraska 68123
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68198
Albuquerque, New Mexico 87102
Clinton, North Carolina 28328
Goldsboro, North Carolina 27534
Jacksonville, North Carolina 28546
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Jamestown, North Dakota 58401
Centerville, Ohio 45459
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45415
Franklin, Ohio 45005-1066
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Troy, Ohio 45373
Oklahoma City, Oklahoma 73104
Bend, Oregon 97701
Clackamas, Oregon 97015
Newberg, Oregon 97132
Ontario, Oregon 97914
Oregon City, Oregon 97045
Portland, Oregon 97213
Portland, Oregon 97225
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19114
Willow Grove, Pennsylvania 19090
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Salt Lake City, Utah 84112
Alexandria, Virginia 22304
Fairfax, Virginia 22031
Fairfax, Virginia 22033
Falls Church, Virginia 22042
Lynchburg, Virginia 24501
Richmond, Virginia 23229
Richmond, Virginia 23235
Richmond, Virginia 23298
Ashland, Wisconsin 54806
Eau Claire, Wisconsin 54701
La Crosse, Wisconsin 54601
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Minocqua, Wisconsin 54548
Mukwonago, Wisconsin 53149
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Superior, Wisconsin 54880
Site Public Contact
701-364-6272
Waukesha, Wisconsin 53188
Site Public Contact
262-928-7632
Waukesha, Wisconsin 53188
More Details
- NCT ID
- NCT05136196
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the feasibility of molecular characterization based on tumor mutation burden (TMB) for participant stratification, as assessed by the proportion of participants with less than or equal to a 21-day turnaround time for biopsy results in Stage I of the study. II. To evaluate the feasibility of molecular characterization based on TMB and gene expression profiling (GEP) (for Tumor Inflammation Score [TIS]) for stratification as assessed by the proportion of participants with less than or equal to a 21-day turnaround time for biopsy results in the overall study (Stage I and Stage II). III. To evaluate the efficacy by overall response rate (ORR - defined as confirmed and unconfirmed partial responses plus complete responses) of cabozantinib S-malate (cabozantinib) plus nivolumab in each disease cohort, both across and within tumor biomarker subgroups. SECONDARY OBJECTIVES: I. To assess the difference in ORR in each disease cohort between tumor marker subgroups separately for each disease cohort. II. To assess safety and tolerability of this treatment in these populations. III. To estimate disease control rate (DCR) in participants receiving cabozantinib plus nivolumab in each disease cohort, stratified by tumor biomarkers. IV. To estimate progression-free survival (PFS) in participants receiving cabozantinib plus nivolumab in each disease cohort, stratified by tumor biomarkers. V. To estimate overall survival (OS) in participants receiving cabozantinib plus nivolumab in each disease cohort, stratified by tumor biomarkers. VI. To assess the proportion of patients with assay failure, and the time from the date of tissue collection to molecular group determination at the end of Stage I. ADDITIONAL OBJECTIVE: I. To identify candidate biomarkers predictive of response and toxicity to the cabozantinib and nivolumab combination. BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle and cabozantinib orally (PO) daily. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) scans and collection of blood samples throughout the trial. Patients undergo a tumor biopsy during screening and optionally during follow-up. After completion of the study treatment, patients are followed for up to 3 years.